chartexchange

Caribou Biosciences to Evaluate Strategic Alternatives

GlobeNewswire Inc. | Oct 6, 2026 4:05 PM EDT

-- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs --

Read original article